NCT02067156View on ClinicalTrials.gov

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

February 28, 2017

Conditions
Glioblastoma Multiforme
Interventions
DRUG

G-202

G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity

Trial Locations (1)

92093

University of California, San Diego Moores Cancer Center, La Jolla

Sponsors

Lead Sponsor

GenSpera, Inc.
All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

lead

GenSpera, Inc.

INDUSTRY